A high-conviction bearish opportunity is identified in ATYR Pharma (ATYR), based on the strong expectation of negative upcoming Phase 3 trial data. The analyst predicts the stock could fall from its current price to around $0.80, suggesting September put options as a way to position for this potential decline. Another key opportunity is shorting Nebius (NBIS), which is seen as fundamentally overvalued after its recent stock surge following a deal with Microsoft. The rationale is that the market has overreacted, adding far more value than the deal's economics justify. A potential entry point to short NBIS is suggested if the stock price remains elevated around the $95-$100 level.

ATYR Pharma (ATYR)

• The speaker has an extremely bearish outlook on ATYR and describes being "all in" on a short position, primarily using put options.
• The entire thesis is based on the expectation that the company's upcoming Phase 3 trial data will be negative.
• The speaker has "very high confidence" that the trial's primary endpoint will not be met.
• Price Prediction: The speaker expects the stock, currently trading at $5.54, to fall to around $0.80 once the negative trial results are released.
• Options Strategy:
  • The speaker analyzes the pricing of various put options, noting the $1 puts (5-10 cents), $2 puts (40-45 cents), $5 puts (1.80-1.85), and $6 puts (2.50-2.60).
  • He explicitly states he "bought a bunch of the puts" and finds the September puts to be attractive at their current prices.
• Comparison: The speaker compares the trade to a previous one in Cassava (SAVA), stating that the ATYR situation is "in some ways... worse than cassava" and "kind of just sad," reinforcing his conviction.

Takeaways

• This is a high-conviction, high-risk bearish trade based on a single upcoming catalyst (Phase 3 data).
• Investors with a high risk tolerance could consider a bearish position, such as buying put options, to speculate on the trial failing as the speaker predicts.
• Risk: This is a "binary event." If the trial data is unexpectedly positive, the stock would likely increase significantly, and any short position or put options would incur substantial, potentially total, losses.

Nebius (NBIS)

• The speaker is bearish on NBIS following the announcement of a $17.4 billion infrastructure deal with Microsoft (MSFT), which caused the stock to rally over 60%.
• He believes the market has overreacted, calling the price "stupid" and comparing the excitement to the ".com" era.
• Valuation Argument: He argues that such deals typically have a 10% margin. Therefore, a $17 billion deal should logically add about $1.7 billion to the company's market cap, not the $6-8 billion increase it saw.
• He was previously short a small amount and states he would "probably short Nubius when I'm back," suggesting a potential short entry point around $95-$100.
• He also questions the quality of the deal, suggesting Microsoft may have negotiated very favorable terms or that it could be a "toxic contract" for Nebius, as other competitors like CoreWeave could have also taken the deal.

Takeaways

• The speaker sees NBIS as fundamentally overvalued after its recent price surge. The core insight is that the market is pricing in far more value from the Microsoft deal than the typical economics of such a contract would justify.
• Investors could consider this a potential short-selling opportunity, especially if the stock price remains elevated or pushes above $100.
• Risk: The primary risk is market momentum. The stock is rallying on strong "AI" and "GPU" narratives, and this positive sentiment could push the price higher regardless of the fundamental valuation argument presented.

Galt Pharmaceuticals (GALT)

• The speaker has a bearish view on GALT and has successfully shorted it in the past ("Gulp went down a lot. We covered it.").
• He is considering shorting the stock again ("excited to short it again?", "Yeah, we'll short galt after this.").
• His thesis is that the stock is popular with retail investors who he believes will eventually lose money, making it an attractive target for a short sale.

Takeaways

• GALT is on the speaker's watchlist as a potential future short.
• Investors who share a bearish view on the company could monitor the stock for signs of retail-driven hype or price run-ups that seem disconnected from fundamentals, which could present a shorting opportunity.

Octo (OCTO)

• The speaker identifies OCTO as another potential short candidate, noting that the stock has gone up 25X.
• The sentiment is bearish, driven by the belief that the massive price increase is unsustainable and likely driven by speculative retail investors ("So many baggies").
• He later expresses some uncertainty, stating, "I don't know what you do with Octo. I don't trade that one," indicating this is not as high-conviction as his ATYR trade.

Takeaways

• OCTO is viewed as a potentially overvalued stock after a significant run-up.
• This could be a stock for bearish-minded investors to watch for signs of weakness or a reversal in momentum. However, the speaker's conviction appears lower here than with other names.